Literature DB >> 18413521

The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study.

Ronald Klein1, Scot E Moss, Stacy M Meuer, Barbara E K Klein.   

Abstract

OBJECTIVES: To describe the 15-year incidence of retinal vein occlusion (central retinal vein occlusion and branch retinal vein occlusion) and associated risk factors.
METHODS: A population-based study where branch retinal vein occlusion and central retinal vein occlusion were detected at baseline (n = 4068, 1988-1990) and three 5-year follow-up examinations by grading 30 degrees color fundus photographs.
RESULTS: The 15-year cumulative incidences of branch retinal vein occlusion and central retinal vein occlusion were 1.8% and 0.5%, respectively. Using a generalized estimating equation model, incident retinal vein occlusion was related to baseline age (odds ratio [OR] per 10 years, 1.70; 95% confidence interval [CI], 1.36-2.12), history of barbiturate use (OR, 5.30; 95% CI, 2.28-12.31), focal retinal arteriolar narrowing (OR, 2.45; 95% CI, 1.29-4.66), glaucoma (OR, 3.17; 95% CI, 1.50-6.69), serum ionized calcium level (OR per 0.4 mg/dL, 0.43; 95% CI, 0.23-0.79), serum phosphorus level (OR per 0.3 mg/dL, 1.15; 95% CI, 1.01-1.30), and serum creatinine level (OR for > or = 1.4 vs < 1.4 mg/dL, 1.61; 95% CI, 1.00-2.59). Migraine headache history was associated with branch retinal vein occlusion (OR, 1.99; 95% CI, 1.08-3.67). Diabetes history was associated with central retinal vein occlusion (OR, 6.35; 95% CI, 1.90-21.27).
CONCLUSIONS: Incident retinal vein occlusion is not infrequent in the population, especially after age 65 years. The relationships of barbiturate use, serum creatinine level, serum ionized calcium level, and serum phosphorus level with incident retinal vein occlusion require further assessment in other large population-based studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413521     DOI: 10.1001/archopht.126.4.513

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  117 in total

Review 1.  Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Aqueous humor inflammatory cytokine levels and choroidal thickness in patients with macular edema associated with branch retinal vein occlusion.

Authors:  Yerim An; Sung Pyo Park; Yong-Kyu Kim
Journal:  Int Ophthalmol       Date:  2021-03-19       Impact factor: 2.031

3.  Predictive factors for recurrence of macular edema after successful intravitreal bevacizumab therapy in branch retinal vein occlusion.

Authors:  Rika Yamada; Akihiro Nishida; Masataka Shimozono; Takanori Kameda; Noriko Miyamoto; Michiko Mandai; Yasuo Kurimoto
Journal:  Jpn J Ophthalmol       Date:  2015-09-03       Impact factor: 2.447

4.  Branch retinal vein occlusion: the importance of the topographical distribution of retinal vessels among risk factors.

Authors:  Z Oztas; C Akkin; S Nalcaci; O Ilim; F Afrashi
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

5.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.

Authors:  Michael S Ip; Ingrid U Scott; Paul C VanVeldhuisen; Neal L Oden; Barbara A Blodi; Marian Fisher; Lawrence J Singerman; Michael Tolentino; Clement K Chan; Victor H Gonzalez
Journal:  Arch Ophthalmol       Date:  2009-09

6.  Risk factors associated with developing branch retinal vein occlusion among enrollees in a United States managed care plan.

Authors:  Paula Anne Newman-Casey; Maxwell Stem; Nidhi Talwar; David C Musch; Cagri G Besirli; Joshua D Stein
Journal:  Ophthalmology       Date:  2014-06-20       Impact factor: 12.079

7.  Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.

Authors:  Yoshitsugu Saishin; Yuka Ito; Masato Fujikawa; Tomoko Sawada; Masahito Ohji
Journal:  Jpn J Ophthalmol       Date:  2016-09-22       Impact factor: 2.447

8.  Influence of diabetes and diabetes type on anatomic and visual outcomes following central rein vein occlusion.

Authors:  J G Santiago; S Walia; J K Sun; J D Cavallerano; Z A Haddad; L P Aiello; P S Silva
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

9.  Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.

Authors:  Rupal Mehta; Gui Shuang Ying; Samuel Houston; Tamara Isakova; Lisa Nessel; Akinlolu Ojo; Alan Go; Jim Lash; John Kusek; Juan Grunwald; Myles Wolf
Journal:  Nephrol Dial Transplant       Date:  2015-04-24       Impact factor: 5.992

10.  Central retinal vein occlusion: a case report and review of the literature.

Authors:  Tarek Alasil; Nahyoung Lee; Pearse Keane; Srinivas Sadda
Journal:  Cases J       Date:  2009-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.